rs149196489
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting
The NM_014679.5(CEP57):āc.422A>Gā(p.Asn141Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000391 in 1,612,850 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N141H) has been classified as Uncertain significance.
Frequency
Consequence
NM_014679.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CEP57 | NM_014679.5 | c.422A>G | p.Asn141Ser | missense_variant | 4/11 | ENST00000325542.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CEP57 | ENST00000325542.10 | c.422A>G | p.Asn141Ser | missense_variant | 4/11 | 1 | NM_014679.5 |
Frequencies
GnomAD3 genomes AF: 0.000236 AC: 36AN: 152240Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000176 AC: 44AN: 250094Hom.: 0 AF XY: 0.000163 AC XY: 22AN XY: 135274
GnomAD4 exome AF: 0.000407 AC: 594AN: 1460610Hom.: 1 Cov.: 31 AF XY: 0.000407 AC XY: 296AN XY: 726646
GnomAD4 genome AF: 0.000236 AC: 36AN: 152240Hom.: 0 Cov.: 33 AF XY: 0.000148 AC XY: 11AN XY: 74372
ClinVar
Submissions by phenotype
Mosaic variegated aneuploidy syndrome 2 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 141 of the CEP57 protein (p.Asn141Ser). This variant is present in population databases (rs149196489, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with CEP57-related conditions. ClinVar contains an entry for this variant (Variation ID: 472257). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CEP57 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 24, 2023 | The c.422A>G (p.N141S) alteration is located in exon 4 (coding exon 4) of the CEP57 gene. This alteration results from a A to G substitution at nucleotide position 422, causing the asparagine (N) at amino acid position 141 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at